Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$102.1M
TTM
Current Assets
$99.58M
Q3 2021
Current Liabilities
$30.30M
Q3 2021
Current Ratio
328.69%
Q3 2021
Total Assets
$105.8M
Q3 2021
Total Liabilities
$34.40M
Q3 2021
Book Value
$71.37M
Q3 2021
Cash
Q3 2021
P/E
-0.4886
Nov 11, 2024 EST
Free Cash Flow
-$94.54M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2020 2019 2018 2017 2016 2015

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2020 2019 2018 2017 2016 2015

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2020 2019 2018 2017 2016 2015

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2020 2019 2018 2017 2016 2015

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2020 2019 2018 2017 2016 2015

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2020 2019 2018 2017 2016 2015

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2020 2019 2018 2017 2016 2015

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $49.87 Million

About Odonate Therapeutics, Inc.

Odonate Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.

Industry: Pharmaceutical Preparations Peers: 9 METERS BIOPHARMA, INC. Aquestive Therapeutics, Inc. Clearside Biomedical, Inc. Enliven Therapeutics, Inc. JOHNSON & JOHNSON OPIANT PHARMACEUTICALS, INC. Longboard Pharmaceuticals, Inc. Medicine Man Technologies, Inc. Mystic Holdings Inc./NV